BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that Seattle Genetics’ management will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “Investor and News” section.
Morgan Stanley Global Healthcare Unplugged Conference
|Tuesday, September 14, 2010|
|3:20 p.m. Eastern Time (ET)|
|New York, NY|
Stifel Nicolaus Healthcare Conference 2010
|Thursday, September 16, 2010|
|2:40 p.m. ET|
UBS Global Life Sciences Conference
|Tuesday, September 21, 2010|
|2:30 p.m. ET|
|New York, NY|
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has five other clinical-stage programs: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70, SGN-75 and ASG-5ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas. More information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
KEYWORDS: United States North America Massachusetts New York Washington
INDUSTRY KEYWORDS: Health Biotechnology Genetics Oncology Pharmaceutical